3E060GN ICD-10-PCS Code: Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach

Related Codes

Same operation — other Body System / Region

Same table and root operation, differing only in the body system / region character.

3E030GN — Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach, 3E040GN — Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach, 3E050GN — Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach

Same operation — other Approach

Same table and root operation, differing only in the approach character.

3E063GN — Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach

Same operation — other Qualifier

Same table and root operation, differing only in the qualifier character.

3E060GC — Introduction of Other Therapeutic Substance into Central Artery, Open Approach

Same procedure category (CCSR), other tables

AHRQ's Clinical Classifications Software Refined groups these ICD-10-PCS procedures with this one under Administration of therapeutic substances, NEC (Administration of Therapeutic Substances); listed here are the members in other PCS tables. Source: Clinical Classifications Software Refined (CCSR), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, November 2025.

XW00X27 — Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7, XW0136A — Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10, XW01397 — Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7, XW013TB — Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11, XW013W5 — Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5, XW01X27 — Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7, XW0333A — Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW03372 — Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2, XW03377 — Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW033F3 — Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3, XW033FA — Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW033FB — Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11, XW033MA — Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW033Q9 — Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9, XW033QB — Introduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11, XW033R9 — Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9, XW033W5 — Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5, XW0433A — Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10, XW04372 — Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2, XW04377 — Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7, +38 more

Contextual Map

Every relationship of 3E060GN in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.

PCS table

• 3E0[PCS table]— CMS ICD-10-PCS tables
• Administration — Section: Administration[Section]: “Administration”— CMS ICD-10-PCS tables
• Physiological Systems and Anatomical Regions — Body System: Physiological Systems and Anatomical Regions[Body System]: “Physiological Systems and Anatomical Regions”— CMS ICD-10-PCS tables
• Introduction — Operation: Introduction[Operation]: “Introduction”— CMS ICD-10-PCS tables

Clinical classification (CCSR)

• ADM021 — Administration of therapeutic substances, NEC[CCSR category]: “Administration of therapeutic substances, NEC — Administration of Therapeutic Substances”— AHRQ CCSR for ICD-10-PCS Procedures (HCUP) · v2026.1

Nearest codes

• 3E030GN — Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach[One axis away]— CMS ICD-10-PCS tables
• 3E040GN — Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach[One axis away]— CMS ICD-10-PCS tables
• 3E050GN — Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach[One axis away]— CMS ICD-10-PCS tables
• 3E060GC — Introduction of Other Therapeutic Substance into Central Artery, Open Approach[One axis away]— CMS ICD-10-PCS tables
• 3E063GN — Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach[One axis away]— CMS ICD-10-PCS tables